GOTHENBERG, Sweden, March 27 /PRNewswire/ -- Cellectricon, a leading provider of screening solutions for drug discovery, today announced the launch of the new Cellaxess(R)HT System. The world's first fully automated high throughput transfection system enables reagent-free delivery of genetic material to a wide range of biologically relevant cell types. The system will be introduced at the SBS 14th Annual Conference and Meeting in St. Louis, MO, USA, April 6-10.
Cellectricon has developed Cellaxess(R)HT in close collaboration with leading research groups to meet the increasing demand for a technology capable of genome-wide RNAi screening.
"We are very pleased to meet the industry's demand by bringing this state-of-the-art system to the market." says Dr. Mattias Karlsson, CEO of Cellectricon. "Cellaxess(R)HT will revolutionize target discovery by opening the door to using more biologically relevant cell types in genome-wide RNAi screening."
About the Cellaxess(R)HT system
Cellaxess(R)HT addresses the critical need for high throughput delivery of siRNA and cDNA to hard to transfect cells in several cell-based screening assays. Cellaxess(R)HT is the only fully automated system on the market allowing for high throughput transfection of cells in culture directly in 384-well microplates. The system enables reagent-free delivery to a wide range of biologically relevant cell types with excellent efficiency and viability at a throughput of 50 000 wells per day.
About Cellectricon
Cellectricon is a key innovator and solutions provider of advanced
cell-based screening products to accelerate biotechnology and drug
discovery. The company's successfully launched products are aimed at
critical bottlenecks in the drug discovery process and have been adopted by
top-reference customers including the top ten pharmaceutical companies. To
date, the company has launched two products with exceptional market
acceptance targeting the ion chann
'/>"/>
| SOURCE Cellectricon AB Copyright©2008 PR Newswire. All rights reserved |